Doc Guide -- Data from 3 randomised trials show that everolimus treatment increases the risk for pericardial effusion compared with azathioprine or mycophenolate mofetil (MMF) regimens in de novo heart transplant recipients, researchers said here at the 23rd International Congress of the Transplant Society (ICTS).
